---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-196040"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:42:16.514616+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Soleno reports Q2 2024 net loss of $21.9M; NDA for DCCR in PWS submitted to FDA

## Summary
- NDA for Diazoxide Choline Extended-Release (DCCR) for Prader-Willi Syndrome with hyperphagia submitted to FDA.
- Cash, cash equivalents and marketable securities of $294.6M as of June 30, 2024.
- Net loss of $21.9M ($0.57 per share) for Q2 2024 vs. $8.5M ($0.81 per share) in Q2 2023.
- R&D expense $12.3M (Q2 2024) up from $5.1M (Q2 2023) due to NDA submission and launch prep.
- Closed $158.7M public offering of 3.45M shares at $46.00 each; BT designation for DCCR granted.

## SEC filing metadata
- accession: 0001193125-24-196040
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312524196040/0001193125-24-196040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312524196040/d892011d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-196040
- JSON: https://secwatch.observer/filing/0001193125-24-196040.json
- Plain text: https://secwatch.observer/filing/0001193125-24-196040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.